Literature DB >> 12717279

An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer.

Hubert G Hotz1, Howard A Reber, Birgit Hotz, Tina Yu, Thomas Foitzik, Heinz J Buhr, Galen Cortina, O Joe Hines.   

Abstract

INTRODUCTION: Orthotopic, clinically relevant animal models are necessary for the study of pathophysiology and therapy for pancreatic cancer. AIMS: To develop a minimally traumatic technique of orthotopic tumor induction, to develop a scoring system to quantify local and systemic tumor spread, and to provide a model with a broad range of well-differentiated to undifferentiated pancreatic cancers.
METHODOLOGY: Orthotopic tumors were induced in nude mice by atraumatic pancreatic implantation of two fragments from subcutaneous donor tumors or intrapancreatic injection of human tumor cells (MIAPaCa-2, AsPC-1, HPAF-2, Capan-1). Animals were monitored for 14 weeks or until death. Primary tumor volume, local infiltration, and systemic metastasis were assessed and analyzed at autopsy. Macroscopic findings were confirmed by histologic evaluation.
RESULTS: Tumor take rate in the implantation group was 100% for all four cell lines. Marked differences with regard to tumor size, metastatic spread, and survival were found depending on the grade of differentiation. Less differentiated cells (MIAPaCa-2, AsPC-1) caused higher dissemination scores and mortality than better-differentiated cells (HPAF-2, Capan-1). Clinical features included cachexia, jaundice, and malignant ascites. Orthotopic tumor cell injection resulted in an incomplete tumor take rate. Moreover, early artificial abdominal tumor spread was found in injected animals due to microscopic cell loss during the injection procedure.
CONCLUSIONS: Orthotopic implantation of donor tumor fragments into nude mice is technically feasible and is superior to the cell injection technique. It results in reproducible local and systemic development of pancreatic cancer that mimics the human disease. A dissemination score may help to better quantify therapeutic effects in future studies.

Entities:  

Mesh:

Year:  2003        PMID: 12717279     DOI: 10.1097/00006676-200305000-00020

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  29 in total

1.  Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.

Authors:  Birgit Hotz; Marina V Backer; Joseph M Backer; Heinz-J Buhr; Hubert G Hotz
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

3.  Development and validation of an intrinsic landmark-based gating protocol applicable for functional and molecular ultrasound imaging.

Authors:  Christoph Grouls; Max Hatting; Isabelle Tardy; Jessica Bzyl; Georg Mühlenbruch; Florian F Behrendt; Tobias Penzkofer; Christian Trautwein; Christiane Kuhl; Fabian Kiessling; Moritz Palmowski
Journal:  Eur Radiol       Date:  2012-03-30       Impact factor: 5.315

4.  Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment.

Authors:  Corina Kim-Fuchs; Caroline P Le; Matthew A Pimentel; David Shackleford; Davide Ferrari; Eliane Angst; Frédéric Hollande; Erica K Sloan
Journal:  Brain Behav Immun       Date:  2014-03-17       Impact factor: 7.217

5.  In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.

Authors:  Birgit Hotz; Ulrich Keilholz; Alberto Fusi; Heinz J Buhr; Hubert G Hotz
Journal:  Gastric Cancer       Date:  2011-10-20       Impact factor: 7.370

6.  Longitudinal Bioluminescence Imaging of Primary Versus Abdominal Metastatic Tumor Growth in Orthotopic Pancreatic Tumor Models in NSG Mice.

Authors:  Harlan E Shannon; Melissa L Fishel; Jingwu Xie; Dongsheng Gu; Brian P McCarthy; Amanda A Riley; Anthony L Sinn; Jayne M Silver; Kacie Peterman; Mark R Kelley; Helmut Hanenberg; Murray Korc; Karen E Pollok; Paul R Territo
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

7.  INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.

Authors:  R Graeser; N Esser; H Unger; I Fichtner; A Zhu; C Unger; F Kratz
Journal:  Invest New Drugs       Date:  2009-01-08       Impact factor: 3.850

8.  An orthotopic nude mouse model for preclinical research of gastric cardia cancer.

Authors:  Sarah Bhargava; Birgit Hotz; Heinz J Buhr; Hubert G Hotz
Journal:  Int J Colorectal Dis       Date:  2008-09-30       Impact factor: 2.571

9.  Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family.

Authors:  Izumi Ohno; Guido Eibl; Irina Odinokova; Mouad Edderkaoui; Robert D Damoiseaux; Moussa Yazbec; Ravinder Abrol; William A Goddard; Osamu Yokosuka; Stephen J Pandol; Anna S Gukovskaya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-09-17       Impact factor: 4.052

10.  The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.

Authors:  Michael D Arensman; Donatello Telesca; Anna R Lay; Kathleen M Kershaw; Nanping Wu; Timothy R Donahue; David W Dawson
Journal:  Mol Cancer Ther       Date:  2014-07-31       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.